---
title: "RBC Capital Sticks to Their Buy Rating for uniQure (QURE)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294352283.md"
description: "RBC Capital analyst Luca Issi reiterated a Buy rating on uniQure (QURE) with a $65 price target, noting the stock closed at $40.07. This follows a recent Buy from Barclays' Eliana Merle, while Goldman Sachs maintains a Hold rating. Issi covers the healthcare sector and has a 39.45% success rate on recommendations."
datetime: "2026-07-30T11:07:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294352283.md)
  - [en](https://longbridge.com/en/news/294352283.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294352283.md)
generator: "portal-rs"
---

# RBC Capital Sticks to Their Buy Rating for uniQure (QURE)

In a report released yesterday, Luca Issi from RBC Capital reiterated a Buy rating on uniQure, with a price target of $65.00. The company’s shares closed yesterday at $40.07.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Issi covers the Healthcare sector, focusing on stocks such as Argenx Se, Alnylam Pharma, and uniQure. According to TipRanks, Issi has an average return of -1.4% and a 39.45% success rate on recommended stocks. 

In addition to RBC Capital, uniQure also received a Buy from Barclays’s Eliana Merle in a report issued today. However, on July 20, Goldman Sachs maintained a Hold rating on uniQure (NASDAQ: QURE).

### Related Stocks

- [QURE.US](https://longbridge.com/en/quote/QURE.US.md)

## Related News & Research

- [uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease | QURE Stock News](https://longbridge.com/en/news/297775517.md)
- [uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says](https://longbridge.com/en/news/297819704.md)
- [09:01 ETHealthcare Is Moving Into the Home. Home Accessibility Now Has a Validated Score.](https://longbridge.com/en/news/297656740.md)
- [Morgans Remains a Buy on EchoIQ Limited (EIQ)](https://longbridge.com/en/news/297720502.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**